Exosomal delivery of miR‐1915‐3p restored oxaliplatin sensitivity in resistant CRC cells by reducing epithelial‐to‐mesenchymal transition (EMT) markers and oncogene expression (PFKFB3, USP2), promoting apoptosis and reducing migration. The gene discussed is USP2; the disease is colorectal carcinoma.